CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.

Autor: Šimi, Iveta, Potočnjak, Ines, Kraljičkovi, Iva, Stanić Beni, Mirjana, Čegec, Ivana, Juričić Nahal, Danica, Ganoci, Lana, Božina, Nada

Publikováno v: Pharmacogenomics; Aug2016, Vol. 17 Issue 13, p1385-1389, 5p

CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.

Autor: Šimić I; University of Zagreb School of Medicine, Zagreb, Croatia.; Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia., Potočnjak I; Clinical Unit of Clinical Pharmacology & Toxicology, Department of Medicine, University Hospital Centre Sisters of Charity, Zagreb, Croatia., Kraljičković I; Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia., Stanić Benić M; Unit for Clinical Pharmacology, University Hospital Centre Rijeka, Rijeka, Croatia., Čegec I; Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia., Juričić Nahal D; Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia., Ganoci L; University of Zagreb School of Medicine, Zagreb, Croatia.; Department of Laboratory Diagnostics, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia., Božina N; University of Zagreb School of Medicine, Zagreb, Croatia.; Department of Laboratory Diagnostics, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia.

Publikováno v: Pharmacogenomics [Pharmacogenomics] 2016 Aug; Vol. 17 (13), pp. 1385-9. Date of Electronic Publication: 2016 Jul 29.